2174264_eisai_logo

Eisai withdraws application for neurodegenerative-disease drug in Japan

March 22, 2016
Manufacturing and Production, Research and Development Eisai, mecobalamin, neurodegenerative disease

Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat …

BioMarin reports mixed Phase III results for genetic disorder trial-drug Pegvaliase

March 22, 2016
Manufacturing and Production, Research and Development

Biotech firm BioMarin Pharmaceutical (Nasdaq: BMRN) reported mixed results for its trial drug to treat genetic disorder phenylketonuria. Trial drug, …

cancer_cells

Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours

March 22, 2016
Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour

Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …

Raptor’s Procysbi gets Priority Review from Health Canada

March 22, 2016
Manufacturing and Production, Research and Development Canada, Health Canada, Procysbi, Raptor Pharmaceutical, genetic condition

Raptor Pharmaceutical (Nasdaq: RPTP) said Canadian regulators have accepted a priority review for its drug to treat a rare genetic …

23andMe’s apps to aid genetic research for Apple’s ResearchKit

March 22, 2016
Manufacturing and Production, Research and Development 23andME, Apple, genetics, research

Privately-held 23andMe has announced a new module for Apple’s (Nasdaq: AAPL) open source ResearchKit software framework that allows scientists to …

peter_bains

Sosei appoints Peter Bains as COO and CEO-elect

March 22, 2016
Research and Development

Japan’s Sosei Group has announced the appointment of Syngene chief executive Peter Bains as representative executive officer and chief operating …

fda_building

FDA bans clinical trial co-ordinator who faked patient samples and stole funds

March 22, 2016
Manufacturing and Production, Medical Communications FDA, HIV, clinical trials, faked, forgery, mcquerry, prison

The US Food and Drug Administration has permanently banned a clinical trial co-ordinator who was found to have falsified patient …

albumedix

Albumedix technology extends dosing interval in Behring haemophilia B drug

March 22, 2016
Manufacturing and Production, Research and Development Albumedix, GSK, Idelvion, Novozymes, VELTIS, haemophilia B

Novozymes subsidiary Albumedix has scored another big pharma tie-up for its albumin-based half-life extension technology VELTIS, which this time is …

disease

FDA approves new anthrax treatment

March 22, 2016
Manufacturing and Production, Research and Development Antibacterial, FDA, US, anthim, anthrax, defense, inhalational

The US Food and Drug Administration (FDA) has approved Anthim (obiltoxaximab) to treat inhalational anthrax in combination with appropriate antibacterial …

takeda_research_centre

Takeda presents long-term Entyvio data in CD and UC

March 21, 2016
Manufacturing and Production, Research and Development Crohn's, Crohn's and Colitis, Entyvio, Takeda, ulcerative colitis

Japan’s Takeda has presented interim findings from the GEMINI Long-Term Safety (LTS) study of ulcerative colitis drug Entyvio (vedolizumab) at …

ThromboGenics signs €1m licensing deal with Galapagos for diabetic eye disease treatment

March 21, 2016
Manufacturing and Production, Research and Development, Sales and Marketing

ThromboGenics NV (Euronext Brussels: THR) on Monday said it has signed a €1 million license deal with Galapagos NV (Nasdaq: …

christa_wirthumer-hoche

European Medicines Agency elects Christa Wirthumer-Hoche as new chair of management board

March 21, 2016
Medical Communications, Research and Development Christa Wirthumer-Hoche, EMA, European Medicines Agency, chair, chairperson, wirthumer-hoche

Christa Wirthumer-Hoche has been elected chair of the management board of the European Medicine’s Agency. She has served as vice …

shutterstock_212432119

Leo Pharma gets EU scientific approval for its psoriasis drug Enstilar

March 21, 2016
Business Services, Research and Development, Sales and Marketing EU, Enstilar, LEO Pharma, psoriasis vulgaris

Leo Pharma on Monday said its drug to treat inflammatory skin condition has received scientific approval in the European Union. …

valeant_sign

Valeant CEO Pearson to leave company

March 21, 2016
Michael Pearson, Valeant

Valeant (NYSE:VRX) has announced that it has begun the search for a new CEO, confirming that Michael Pearson is to …

orexo_logo

AstraZeneca buys rights to Orexo respiratory programme

March 21, 2016
Sales and Marketing AstraZeneca, COPD, asthma, orexo

AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million. The deal centres on the …

novartissunlight_copy

Novartis’s heart failure drug given final recommendation by NICE

March 21, 2016
Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug

The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …

zytiga

NICE approves Janssen’s Zytiga for prostate cancer before chemo

March 21, 2016
Sales and Marketing Janssen, NICE, Zytiga, prostate cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat …

TREND: Smallcap biotechs win in stock markets on positive drug trials

March 21, 2016
Research and Development, Sales and Marketing

Troubled Canadian drug firm Valeant Pharma (NYSE: VRX) saw its share price halved in a single day after the company …

pfizer_logo

Pfizer India names S Sridhar MD

March 21, 2016
Business Services, Sales and Marketing Executive appointment, Pfizer Inc, Pfizer India

Pfizer India (BOM: 500680) has named S Sridhar the company’s managing director for a five-year term, effective March 18. Sridhar …

tablet_production_2

Further positive trial results boost Amgen and UCB’s romosozumab

March 21, 2016
Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval

Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …

The Gateway to Local Adoption Series

Latest content